OCGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ocugen's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 6.25%.
Ocugen's EBITDA per Share for the three months ended in Sep. 2024 was $-0.05.
The historical data trend for Ocugen's YoY EBITDA Growth can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocugen Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
YoY EBITDA Growth | Get a 7-Day Free Trial | 96.77 | 85.89 | -58.29 | -39.53 | 35.84 |
Ocugen Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
YoY EBITDA Growth | Get a 7-Day Free Trial | 54.72 | 65.63 | 40.51 | 40.82 | 6.25 |
YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.
Ocugen's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:
YoY EBITDA Growth (A: Dec. 2023 ) | |||||
= | (EBITDA per Share (A: Dec. 2023 ) | - | EBITDA per Share (A: Dec. 2022 )) | / | | EBITDA per Share (A: Dec. 2022 ) | |
= | (-0.265 | - | -0.413) | / | | -0.413 | |
= | 35.84 % |
Ocugen's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:
YoY EBITDA Growth (Q: Sep. 2024 ) | |||||
= | (EBITDA per Share (Q: Sep. 2024 ) | - | EBITDA per Share (Q: Sep. 2023 )) | / | | EBITDA per Share (Q: Sep. 2023 )) | |
= | (-0.045 | - | -0.048) | / | | -0.048 | |
= | 6.25 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ocugen's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.
Prabhavathi Fernandes | director | 114 MILTON AVENUE, CHAPEL HILL NC 27514 |
Kirsten Castillo | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Junge Zhang | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Quan Anh Vu | officer: CFO/CBO | 22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
Shankar Musunuri | director, officer: Chief Executive Officer | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Arun Upadhyay | officer: Chief Scientific Officer | C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
Ramesh Kumar | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Uday Kompella | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Marna C Whittington | director | 2959 BARLEY MILL ROAD, YORKLYN DE 19736 |
Jessica Crespo | officer: CAO/SVP, Finance | C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
Sanjay Subramanian | officer: Chief Financial Officer | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Manish Potti | director | C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355 |
Vijay Tammara | officer: Vice President | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Suha Taspolatoglu | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Kelly Beck | officer: Vice President | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
From GuruFocus
By Marketwired • 07-25-2024
By Marketwired • 08-02-2024
By Marketwired • 10-22-2024
By Marketwired • 08-28-2024
By Marketwired • 09-09-2024
By Marketwired • 07-29-2024
By Marketwired • 10-10-2024
By Marketwired • 10-28-2024
By Marketwired • 09-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.